Evaluation of the Efficacy of Riamilovir and Oseltamivir Combination on the Experimental Model of Mice Influenza Infection

Riamilovir (Triazavirin®) Is an original Russian preparation of the azoloazine family, an analogue of the purine nucleoside (guanosine), it belongs to inhibitors of the synthesis of viral RNAs and replicators of genomic fragments. The drug has a wide spectrum of antiviral activity, is effective for a number of acute respiratory viral infections, including influenza A and B, and is included in clinical recommendations for treatment of influenza in adults. The aim of this work is to study the efficacy of a combination of riamilovir and oseltamivir in different doses on a model of viral influenza pneumonia in mice. The efficacy of the drugs was evaluated by increasing the survival rate and reducing the loss of body weight of mice, changing the titer of the virus in the lungs, the morphological state of the lungs, and also increasing the life span of animals compared to control animals that were not treated. In the experimental model of viral influenza pneumonia in mice in two experiments with low and high doses of infection showed with the use of clinical, virological, and morphological parameters that the combination of riamilovir in doses of 12.5 or 25 mg/kg/day with oseltamivir at a dose of 5 mg/kg/day makes it possible to increase the effectiveness of treatment compared to the effectiveness of separate treatment with each drug in the appropriate dose and according to the corresponding scheme. This treatment showed a statistically significant reduction in animal mortality, prevented their loss of body weight, and prolonged life expectancy compared to the control group of animals that did not receive treatment. The combination of riamilov at a dose of 12.5 mg/kg/day with oseltamivir had a therapeutic effect on the morphological state of the lungs. Furthermore, said combinations of drugs significantly reduced the multiplication of the virus in the lungs of animals when infected with a low dose of the virus and suppressed the reproduction of the virus completely at a high dose of infection.

influenza virus, antiviral drugs, riamilovir, oseltamivir, combined action

1. Govorkova E. A., Webster R. G. Combination chemotherapy for influenza. Viruses. 2010 Aug; 2 (8): 1510-1529.

2. Nguyen J.T, Hoopes J.D., Le M.H. et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5 (2): e9332.

3. Leneva I.A. Medical agent for treating viral infections. Patent: International Pub. No. WO/2007/075102: International Application No.: PCT/RU2005/000677, 2007.

4. Ленёва H.A., Федякина И.Т., Гуськова Т.А., Глушков Р.Г. Чувствительность различных штаммов вируса гриппа к арбидолу. Изучение эффекта арбидола на репродукцию вируса гриппа А в комбинации с различными противовирусными препаратами. Терапевтический архив. - 2005. - № 8. - C. 84-88

5. Чупахин O.H., Киселев О. И., редакторы. Триазавирин - противовирусный препарат нового поколения. Монография, 2016

6. Тихонова E. П., Кузьмина Т. Ю., Андронова Н. В., Тюшевская О. А., Елистратова Т. А., Кузьмин A. E. Изучение эффективности противовирусных препаратов (умифеновира, триазавирина) в отношении острых респираторных вирусных инфекций. Казанский медицинский журнал. - 2018. - Т. 99. - № 2

7. Логинова С. Я., Борисевич С. В., Максимов В. А. и др. Изучение противовирусной активности триазавирина в отношении возбудителя гриппа А (H5N1). Антибиотики и химиотер. - 2007. - Т. 52. - № 11-12. - С . 18-20

8. Leneva I. A., Falynskova I. N., Makhmudova N. R., Glubokova E. A., Kartasheva N. P., Leonova E. I., Mikhailova N. A., Shestakova I. V. Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice. Microbiol Independ Res (MIR) 2017; 4 (1): 52-57

9. Федеральные клинические рекомендации под редакцией Международной ассоциации специалистов в области инфекций (МАСОИ) «Грипп у взрослых», 2017. - С. 32

10. Клинические рекомендации ассоциаций «Национальное научное общество инфекционистов» и «Общероссийская общественная организация Российское научное медицинское общество терапевтов», 2017. - С. 29

11. риазавирин (Triazavirin) инструкция по применению, регистрационный номер ЛП-002604

12. Hurt A.C. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 2014; 8: 22-29